This is why Verona Pharma plc (VRNA) Stock is one of the options for the Longer run

A share price of Verona Pharma plc [VRNA] is currently trading at $12.56, up 0.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRNA shares have gain 4.23% over the last week, with a monthly amount glided 11.64%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 9, November 2022, Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Access to up to $400 million expected to provide cash runway through at least 2025.

From an analyst’s perspective:

Previously, Piper Sandler started tracking the stock with Overweight rating on August 26, 2022, and set its price target to $31. On September 13, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $17 on August 25, 2020. Canaccord Genuity initiated its recommendation with a Buy and recommended $17 as its price target on August 10, 2020. BTIG Research started tracking with a Buy rating for this stock on April 18, 2019, and assigned it a price target of $17.

Verona Pharma plc experienced fluctuations in its stock price throughout the past year between $3.41 and $14.69. Currently, Wall Street analysts expect the stock to reach $25.43 within the next 12 months. Verona Pharma plc [NASDAQ: VRNA] shares were valued at $12.56 at the most recent close of the market. An investor can expect a potential return of 102.47% based on the average VRNA price forecast.

Analyzing the VRNA fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.35 points at the first support level, and at 12.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.86, and for the 2nd resistance point, it is at 13.16.

Verona Pharma plc [VRNA] reported earnings per share of -$0.32 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.38/share, meaning a difference of $0.06 and a surprise factor of 15.80%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.4 per share as compared to estimates of -$0.44 per share, a difference of $0.04 representing a surprise of 9.10%.

Ratios To Look Out For

A current ratio of 8.00 is a noteworthy aspect of Verona Pharma plc [NASDAQ:VRNA]. In addition, the Quick Ratio stands at 5.09 and the Cash Ratio stands at 4.44. Considering the valuation of this stock, the price to sales ratio is 9.94, the price to book ratio is 2.72.

Transactions by insiders

Recent insider trading involved Hahn Mark W, Chief Financial Officer, that happened on Nov 01 when 13160.0 shares were sold. Chief Medical Officer, Rickard Kathleen A. completed a deal on Nov 01 to sell 28752.0 shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 32904.0 shares on Nov 01.